Sparkle Clean Tech Licenses Oil & Gas Water Treatment Technologies from Siemens Energy, Inc.
20.1.2025 12:03:00 CET | Business Wire | Press release
This License expands Sparkle's portfolio for sustainable, integrated water solutions that support oil and gas exploration and production and support customers' waste and efficiency goals.
Sparkle Clean Tech, a global provider of process technologies and value-driven energy solutions for upstream Oil and Gas customers, is pleased to announce that it has reached an agreement with Siemens Energy to license Intellectual Property from their upstream oil and gas related water solutions technology portfolio. The license includes technologies for primary, secondary and tertiary oily water treatment, such as Corrugated Plates, Hydrocyclones, Flotation Units, Walnut Shell filters, as well as regenerable membrane-based treatment technologies. This license includes intellectual property such as patents, copyrights and trade secrets. The technologies effectively address the water and wastewater needs of the oil and gas industry.
Sparkle Clean Tech will license Siemens Energy's Monosep™ Nutshell Filtration; Perfomedia™ adsorption technology; Veirsep™ and Spinsep™ Flotation with Brise DGF Pumps or Eductors; FoldedFlo™ DAF; Liquid/Liquid Hydro cyclones with TL1.05™ Liners; and Corrugated Plate separators, along with the associated intellectual property.
The integration of these technologies will expand Sparkle Clean Tech's portfolio of sustainable and integrated offerings into the treatment of water and wastewater produced in Oil & Gas exploration and production facilities.
Mike Foster, Director of Sparkle Clean Tech, stated, "Water and wastewater management in Oil & Gas exploration and production is critical for our customers who are looking for answers to improve efficiency, make their operations more sustainable, and comply with environmental regulations and standards. This license adds to our growing integrated technology portfolio and provides yet another sustainable solution for our customers."
Sumeet Mehra, CEO Sparkle Clean Tech, stated further "We are thrilled to announce the licence of Siemens Energy's oil and gas water and wastewater treatment technologies. This strategic move reinforces our commitment to providing comprehensive and sustainable solutions to our customers in the oil and gas industry. The addition of these cutting-edge technologies to our portfolio not only expands our capabilities but also strengthens our position as a leader in integrated water solutions. We are confident that these licenses will play a significant role in supporting our customers' waste and efficiency goals while contributing to the preservation of our environment."
The licensed portfolio of technologies focuses on the treatment of oil & gas wastewater from production wells, while the Brise & Perfomedia process offers an efficient wastewater treatment solution designed to remove pollutants from produced wastewater. Both processes offer significant advancements in waste management within the oil and gas industry.
Sparkle Clean Tech is committed to driving innovation and sustainability within the oil and gas sector. By licensing Siemens Energy's upstream water treatment technologies, Sparkle Clean Tech aims to offer comprehensive solutions that support customers' waste and efficiency goals, while also contributing to environmental preservation.
About Sparkle Clean Tech:
Sparkle Clean Tech is a global provider of process technologies and value-driven energy solutions for upstream Oil and Gas customers. With a focus on sustainability and innovation, Sparkle Clean Tech aims to optimize operations and support customers' environmental goals while driving efficiency and profitability.
Sparkle Clean Tech’s other solutions include treatment technologies for water and wastewater management. Utilizing specialized Ultrafiltration, Reverse Osmosis, Desalination, and High Purity Water technologies, Sparkle addresses the needs of diverse industries including Lithium, Microelectronics, Mining among others. With a global customer footprint, Sparkle has executed several projects in the Americas, Europe, Asia, and the Middle East.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250120193068/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom